ArticleJAC-antimicrobial resistance2026
Treatment outcomes of daptomycin- and vancomycin-resistant
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Among patients with daptomycin-resistant and vancomycin-resistant Methods: Adults with VRE BSI who received linezolid or daptomycin ≥8 mg/kg were included. Results: Among 130 patients with daptomycin-resistant VRE BSI, 110 received daptomycin and 20 received linezolid. Within the daptomycin group, 28-day mortality was 55.1% (43/78) with daptomycin 8 to <11 mg/kg and 34.4% (11/32) with daptomycin ≥11 mg/kg. In adjusted analysis, daptomycin 8 to <11 mg/kg was associated with higher mortality than daptomycin ≥11 mg/kg [adjusted odds ratio (aOR) 3.11, 95% CI 1.13 to 8.56, Conclusions: In daptomycin-resistant VRE BSI, daptomycin ≥11 mg/kg was associated with lower 28-day mortality than daptomycin 8 to <11 mg/kg, particularly at MIC = 8 mg/L. Comparisons with the small linezolid arm are exploratory and underpowered. Larger studies are needed to confirm these hypothesis-generating findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.